Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

NAC1, a BTB/POZ protein overexpressed in uterine sarcomas.

Rahman MT, Nakayama K, Ishikawa M, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Yamada T, Miyazaki K.

Anticancer Res. 2012 Sep;32(9):3841-5.

PMID:
22993327
2.

Biological role and prognostic significance of NAC1 in ovarian cancer.

Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.

Gynecol Oncol. 2010 Dec;119(3):469-78. doi: 10.1016/j.ygyno.2010.08.031. Epub 2010 Sep 24.

PMID:
20869761
3.

Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.

D'Angelo E, Spagnoli LG, Prat J.

Hum Pathol. 2009 Nov;40(11):1571-85. doi: 10.1016/j.humpath.2009.03.018. Epub 2009 Jun 21.

PMID:
19540555
4.

Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.

Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, Ueland FR, van Nagell JR, Ahmed MM, Lele SM.

Gynecol Oncol. 2003 Oct;91(1):9-14.

PMID:
14529657
5.

NAC1, a potential stem cell pluripotency factor expression in normal endometrium, endometrial hyperplasia and endometrial carcinoma.

Ishikawa M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K.

Int J Oncol. 2010 May;36(5):1097-103.

PMID:
20372782
6.

Expression of a BTB/POZ protein, NAC1, is essential for the proliferation of normal cyclic endometrial glandular cells and is up-regulated by estrogen.

Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K.

Clin Cancer Res. 2009 Feb 1;15(3):804-11. doi: 10.1158/1078-0432.CCR-08-2134.

7.

Low expression of nucleus accumbens-associated protein 1 predicts poor prognosis for patients with pancreatic ductal adenocarcinoma.

Nishi T, Maruyama R, Urano T, Nakayama N, Kawabata Y, Yano S, Yoshida M, Nakayama K, Miyazaki K, Takenaga K, Tanaka T, Tajima Y.

Pathol Int. 2012 Dec;62(12):802-10. doi: 10.1111/pin.12020.

PMID:
23252869
8.

Uterine sarcomas: a review.

D'Angelo E, Prat J.

Gynecol Oncol. 2010 Jan;116(1):131-9. doi: 10.1016/j.ygyno.2009.09.023. Epub 2009 Oct 23. Review.

PMID:
19853898
9.

ERBB-2 gene overexpression and amplification in uterine sarcomas.

Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, Vergote I.

Gynecol Oncol. 2004 Dec;95(3):583-7.

PMID:
15581967
10.

Biological and clinical significance of NAC1 expression in cervical carcinomas: a comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas.

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Otuski Y, Kobayashi H, Nakayama S, Miyazaki K.

Hum Pathol. 2012 Apr;43(4):506-19. doi: 10.1016/j.humpath.2011.05.021. Epub 2011 Sep 1.

PMID:
21889186
11.

The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.

Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O'Meara AT, Amezcua CA.

Gynecol Oncol. 2003 Aug;90(2):402-6.

PMID:
12893208
12.

ERBB2 (HER2) protein expression in uterine sarcomas.

Zafrakas M, Zepiridis L, Theodoridis TD, Venizelos ID, Papanicolaou A, Agorastos T, Bontis JN.

Eur J Gynaecol Oncol. 2009;30(3):292-4.

PMID:
19697624
13.

Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.

Arita S, Kikkawa F, Kajiyama H, Shibata K, Kawai M, Mizuno K, Nagasaka T, Ino K, Nomura S.

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):329-36.

PMID:
15823121
14.

Prognostic factors in uterine sarcoma.

Gadducci A.

Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):783-95. doi: 10.1016/j.bpobgyn.2011.06.002. Epub 2011 Jul 18. Review.

PMID:
21764643
15.

NAC1, a POZ/BTB protein that functions as a corepressor.

Korutla L, Wang P, Jackson TG, Mackler SA.

Neurochem Int. 2009 Mar-Apr;54(3-4):245-52. doi: 10.1016/j.neuint.2008.12.008. Epub 2008 Dec 13.

PMID:
19121354
16.

Ultrasound findings in uterine mixed müllerian sarcomas and endometrial stromal sarcomas.

Cacciatore B, Lehtovirta P, Wahlström T, Ylöstalo P.

Gynecol Oncol. 1989 Dec;35(3):290-3.

PMID:
2689303
17.

Identification of suitable reference genes for gene expression measurement in uterine sarcoma and carcinosarcoma tumors.

Kowalewska M, Danska-Bidzinska A, Bakula-Zalewska E, Bidzinski M.

Clin Biochem. 2012 Mar;45(4-5):368-71. doi: 10.1016/j.clinbiochem.2012.01.001. Epub 2012 Jan 13.

PMID:
22266404
18.

Endocrine aspects of human uterine sarcoma: a preliminary study.

Tseng L, Tseng JK, Mann WJ, Chumas JC, Stone ML, Mazella J, Sun B, Amalfitano TG, Wallach RC.

Am J Obstet Gynecol. 1986 Jul;155(1):95-101.

PMID:
2942037
19.

Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo.

Zhou J, Peng C, Li B, Wang F, Zhou C, Hong D, Ye F, Cheng X, Lü W, Xie X.

Gynecol Oncol. 2012 Feb;124(2):296-302. doi: 10.1016/j.ygyno.2011.10.028. Epub 2011 Nov 3.

PMID:
22056554
20.

The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas.

Tamai K, Koyama T, Saga T, Morisawa N, Fujimoto K, Mikami Y, Togashi K.

Eur Radiol. 2008 Apr;18(4):723-30. Epub 2007 Oct 10.

PMID:
17929022

Supplemental Content

Support Center